Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Roy, A. Stewart, P. Bergsagel, A. Dispenzieri, K. Laumann, J. Allred, M. Lacy, R. Fonseca, C. Reeder, Shaji Kumar, C. Rivera, M. Gertz, F. Buadi, S. Hayman, S. Rajkumar (2015)
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantationBlood Cancer Journal, 5
N. Lendvai, P. Hilden, S. Devlin, H. Landau, H. Hassoun, A. Lesokhin, Ioanna Tsakos, Kaitlyn Redling, G. Koehne, D. Chung, Wendy Schaffer, S. Giralt (2014)
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.Blood, 124 6
A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni, A. Romano, F. Patriarca, D. Rossi, F. Gentilini, C. Crippa, M. Galli, C. Nozzoli, R. Ria, R. Marasca, V. Montefusco, L. Baldini, F. Elice, V. Callea, S. Pulini, A. Carella, R. Zambello, G. Benevolo, V. Magarotto, P. Tacchetti, N. Pescosta, C. Cellini, C. Polloni, A. Evangelista, T. Caravita, F. Morabito, M. Offidani, P. Tosi, M. Boccadoro (2011)
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
L. Hicks, A. Haynes, D. Reece, I. Walker, J. Herst, R. Meyer, K. Imrie (2008)
A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.Cancer treatment reviews, 34 5
H. Lokhorst, B. Holt, S. Zweegman, E. Vellenga, S. Croockewit, M. Oers, P. Borne, P. Wijermans, R. Schaafsma, O. Weerdt, S. Wittebol, M. Delforge, H. Berenschot, G. Bos, K. Jie, H. Sinnige, M. Marwijk-Kooy, P. Joosten, M. Minnema, Rianne Ammerlaan, P. Sonneveld (2010)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.Blood, 115 6
P. Richardson, S. Jagannath, M. Hussein, J. Berenson, S. Singhal, David Irwin, S. Williams, W. Bensinger, A. Badros, R. Vescio, Laurie Kenvin, Zhinuan Yu, M. Olesnyckyj, J. Zeldis, R. Knight, K. Anderson (2009)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.Blood, 114 4
H. Lokhorst, I. Schmidt-Wolf, P. Sonneveld, B. Holt, H. Martin, R. Barge, U. Bertsch, Jana Schlenzka, G. Bos, S. Croockewit, S. Zweegman, I. Breitkreutz, P. Joosten, C. Scheid, M. Marwijk-Kooy, H. Salwender, M. Oers, R. Schaafsma, R. Naumann, H. Sinnige, I. Blau, M. Delforge, O. Weerdt, P. Wijermans, S. Wittebol, Ulrich Duersen, E. Vellenga, H. Goldschmidt (2008)
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHaematologica, 93
Keren Osman, R. Comenzo, S. Rajkumar (2001)
Deep venous thrombosis and thalidomide therapy for multiple myeloma.The New England journal of medicine, 344 25
T. Bagratuni, E. Kastritis, M. Politou, M. Roussou, E. Kostouros, M. Gavriatopoulou, E. Eleutherakis-Papaiakovou, Nikolaos Kanelias, E. Terpos, M. Dimopoulos (2013)
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide‐based regimensAmerican Journal of Hematology, 88
A. Palumbo, P. Falco, P. Corradini, A. Falcone, F. Raimondo, N. Giuliani, C. Crippa, G. Ciccone, P. Omedè, M. Ambrosini, F. Gay, S. Bringhen, P. Musto, R. Foà, R. Knight, J. Zeldis, M. Boccadoro, M. Petrucci (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 28
M. Hussein, R. Baz, G. Srkalović, N. Agrawal, R. Suppiah, E. Hsi, S. Andresen, M. Karam, J. Reed, B. Faiman, M. Kelly, Esteban Walker (2006)
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.Mayo Clinic proceedings, 81 7
M. Cavo, E. Zamagni, P. Tosi, C. Cellini, D. Cangini, P. Tacchetti, N. Testoni, M. Tonelli, A. Vivo, G. Palareti, S. Tura, M. Baccarani (2004)
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.Haematologica, 89 7
M. Offidani, L. Corvatta, M. Marconi, G. Visani, F. Alesiani, M. Brunori, P. Galieni, M. Catarini, M. Burattini, R. Centurioni, S. Rupoli, A. Scortechini, L. Giuliodori, M. Candela, D. Capelli, M. Montanari, A. Olivieri, Maria‐Novella Piersantelli, P. Leoni (2006)
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.Haematologica, 91 1
A. Palumbo, S. Rajkumar, J. Miguel, A. Larocca, R. Niesvizky, G. Morgan, O. Landgren, R. Hájek, H. Einsele, K. Anderson, M. Dimopoulos, P. Richardson, M. Cavo, A. Spencer, A. Stewart, K. Shimizu, S. Lonial, P. Sonneveld, B. Durie, P. Moreau, R. Orlowski (2014)
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 6
S. Kristinsson, R. Pfeiffer, M. Björkholm, L. Goldin, S. Schulman, C. Blimark, U. Mellqvist, A. Wåhlin, I. Turesson, O. Landgren (2009)
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.Blood, 115 24
SY Kristinsson, RM Pfeiffer, M Björkholm, S Schulman, O Landgren (2012)
Thrombosis is associated with inferior survival in multiple myeloma, 97
David Johnson, S. Corthals, C. Ramos, A. Hoering, Kim Cocks, N. Dickens, J. Haessler, H. Goldschmidt, J. Child, S. Bell, G. Jackson, D. Baris, S. Rajkumar, Faith Davies, B. Durie, J. Crowley, P. Sonneveld, Brian Ness, G. Morgan (2008)
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Blood, 112 13
S. Rajkumar, L. Rosiñol, M. Hussein, J. Catalano, W. Jędrzejczak, L. Lucy, M. Olesnyckyj, Zhinuan Yu, R. Knight, J. Zeldis, J. Bladé (2008)
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 13
D. Siegel, T. Martin, A. Nooka, R. Harvey, R. Vij, R. Niesvizky, A. Badros, S. Jagannath, L. Mcculloch, K. Rajangam, S. Lonial (2013)
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesHaematologica, 98
J. Zonder, J. Crowley, M. Hussein, V. Bolejack, D. Moore, Brock Whittenberger, M. Abidi, B. Durie, B. Barlogie (2010)
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).Blood, 116 26
M. Dimopoulos, A. Spencer, M. Attal, H. Prince, J. Harousseau, A. Dmoszyńska, J. Miguel, A. Hellmann, T. Facon, R. Foà, A. Corso, Z. Masliak, M. Olesnyckyj, Zhinuan Yu, J. Patin, J. Zeldis, R. Knight (2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.The New England journal of medicine, 357 21
D. Weber, K. Rankin, M. Gavino, K. Delasalle, R. Alexanian (2003)
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 1
P. Richardson, R. Schlossman, S. Jagannath, M. Alsina, R. Desikan, E. Blood, E. Weller, C. Mitsiades, T. Hideshima, F. Davies, D. Doss, A. Freeman, J. Bosch, J. Patin, R. Knight, J. Zeldis, W. Dalton, K. Anderson (2004)
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.Mayo Clinic proceedings, 79 7
P. Schütt, P. Ebeling, U. Buttkereit, D. Brandhorst, B. Opalka, M. Hoiczyk, M. Flasshove, J. Hense, P. Bojko, K. Metz, T. Moritz, S. Seeber, M. Nowrousian (2005)
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myelomaEuropean Journal of Haematology, 74
P. Richardson, D. Siegel, R. Vij, C. Hofmeister, R. Baz, S. Jagannath, Christine Chen, S. Lonial, A. Jakubowiak, N. Bahlis, K. Song, A. Belch, N. Raje, C. Shustik, S. Lentzsch, M. Lacy, J. Mikhael, J. Matous, D. Vesole, Min Chen, M. Zaki, C. Jacques, Zhinuan Yu, K. Anderson (2014)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.Blood, 123 12
A. Palumbo, S. Bringhen, T. Caravita, E. Merla, V. Capparella, V. Callea, C. Cangialosi, M. Grasso, F. Rossini, M. Galli, L. Catalano, E. Zamagni, M. Petrucci, V. Stefano, M. Ceccarelli, M. Ambrosini, I. Avonto, P. Falco, G. Ciccone, A. Liberati, P. Musto, M. Boccadoro (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 367
S. Rajkumar, S. Jacobus, N. Callander, R. Fonseca, D. Vesole, M. Williams, R. Abonour, D. Siegel, M. Katz, P. Greipp (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.The Lancet. Oncology, 11 1
S. Knop, C. Gerecke, P. Liebisch, M. Topp, U. Platzbecker, O. Sezer, Christina Vollmuth, K. Falk, A. Glasmacher, U. Maeder, H. Einsele, R. Bargou (2009)
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).Blood, 113 18
A. Palumbo, A. Bertola, P. Musto, T. Caravita, V. Callea, M. Nunzi, M. Grasso, P. Falco, C. Cangialosi, M. Boccadoro (2005)
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myelomaCancer, 104
Yi Xiao, Jin Yin, Jia Wei, Z. Shang (2014)
Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-AnalysisPLoS ONE, 9
A. Anagnostopoulos, D. Weber, K. Rankin, K. Delasalle, R. Alexanian (2003)
Thalidomide and dexamethasone for resistant multiple myelomaBritish Journal of Haematology, 121
E. Orciuolo, G. Buda, N. Cecconi, S. Galimberti, D. Versari, G. Cervetti, A. Salvetti, M. Petrini (2007)
Unexpected cardiotoxicity in haematological bortezomib treated patientsBritish Journal of Haematology, 138
P. Richardson, E. Blood, C. Mitsiades, S. Jagannath, S. Zeldenrust, M. Alsina, R. Schlossman, S. Rajkumar, K. Desikan, T. Hideshima, Nikhil Munshi, Kathleen Kelly-Colson, D. Doss, M. Mckenney, S. Gorelik, D. Warren, A. Freeman, Rebecca Rich, A. Wu, M. Olesnyckyj, K. Wride, W. Dalton, J. Zeldis, R. Knight, E. Weller, K. Anderson (2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.Blood, 108 10
J. Pagan, T. Seto, M. Pagano, A. Cittadini (2013)
Role of the Ubiquitin Proteasome System in the HeartCirculation Research, 112
S. Kristinsson, R. Pfeiffer, M. Björkholm, S. Schulman, O. Landgren
Articles and Brief Reports Design and Methods Thrombosis Is Associated with Inferior Survival in Multiple Myeloma
S. Schey, J. Cavenagh, R. Johnson, J. Child, H. Oakervee, R. Jones (2003)
An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.Leukemia research, 27 10
G. Lu, R. Middleton, Huahang Sun, MarkVic Naniong, Christopher Ott, C. Mitsiades, Kwok-kin Wong, J. Bradner, W. Kaelin (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsScience, 343
R. Rosovsky, F. Hong, D. Tocco, Brendan Connell, C. Mitsiades, R. Schlossman, I. Ghobrial, L. Lockridge, D. Warren, G. Bradwin, M. Doyle, N. Munshi, R. Soiffer, K. Anderson, E. Weller, P. Richardson (2013)
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational studyBritish Journal of Haematology, 160
S. Danhof, M. Schreder, L. Rasche, Susanne Strifler, H. Einsele, S. Knop (2016)
‘Real‐life’ experience of preapproval carfilzomib‐based therapy in myeloma – analysis of cardiac toxicity and predisposing factorsEuropean Journal of Haematology, 97
S. Meiners, H. Dreger, M. Fechner, Sven Bieler, W. Rother, C. Günther, G. Baumann, V. Stangl, K. Stangl (2008)
Suppression of Cardiomyocyte Hypertrophy by Inhibition of the Ubiquitin-Proteasome SystemHypertension, 51
Raina Pn, C. Ramakrishnan (1964)
Pharmacology, pharmacokinetics, and practical applications of bortezomib.Oncology, 18
Choon-kee Lee, B. Barlogie, N. Munshi, M. Zangari, A. Fassas, J. Jacobson, F. Rhee, M. Cottler-Fox, F. Muwalla, G. Tricot (2003)
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
C. Mitsiades (2015)
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 7
A. Palumbo, S. Rajkumar, M. Dimopoulos, P. Richardson, J. Miguel, B. Barlogie, J. Harousseau, J. Zonder, M. Cavo, M. Zangari, M. Attal, A. Belch, S. Knop, D. Joshua, O. Sezer, H. Ludwig, D. Vesole, J. Bladé, R. Kyle, J. Westin, D. Weber, S. Bringhen, R. Niesvizky, A. Waage, M. Lilienfeld-Toal, S. Lonial, G. Morgan, R. Orlowski, K. Shimizu, K. Anderson, M. Boccadoro, B. Durie, P. Sonneveld, M. Hussein (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 22
P. Richardson, R. Schlossman, E. Weller, T. Hideshima, C. Mitsiades, F. Davies, R. LeBlanc, L. Catley, D. Doss, K. Kelly, M. Mckenney, Julie Mechlowicz, A. Freeman, Reggie Deocampo, Rebecca Rich, J. Ryoo, D. Chauhan, Kathe Balinski, J. Zeldis, K. Anderson (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.Blood, 100 9
D. Pulte, M. Redaniel, L. Lowry, J. Bird, M. Jeffreys (2014)
Age disparities in survival from lymphoma and myeloma: a comparison between US and EnglandBritish Journal of Haematology, 165
M. Zangari, E. Siegel, B. Barlogie, E. Anaissie, Fariba Saghafifar, A. Fassas, C. Morris, L. Fink, G. Tricot (2002)
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.Blood, 100 4
K. Papadopoulos, D. Siegel, D. Vesole, Peter Lee, S. Rosen, N. Zojwalla, J. Holahan, Susan Lee, Zhengping Wang, A. Badros (2015)
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 7
D. Weber, Christine Chen, R. Niesvizky, Michael Wang, A. Belch, E. Stadtmauer, D. Siegel, I. Borrello, S. Rajkumar, A. Chanan-Khan, S. Lonial, Zhinuan Yu, J. Patin, M. Olesnyckyj, J. Zeldis, R. Knight (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.The New England journal of medicine, 357 21
M. Offidani, M. Marconi, L. Corvatta, A. Olivieri, M. Catarini, P. Leoni (2003)
Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.Haematologica, 88 12
H. Quach, D. Ritchie, D. Ritchie, A. Stewart, P. Neeson, S. Harrison, M. Smyth, H. Prince, H. Prince (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia, 24
P. Bernardeschi, G. Giustarini, I. Montenora, G. Turrisi, P. Dentico, S. Rossi, E. Turano, G. Fiorentini (2006)
Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.In vivo, 20 6A
S. Atrash, A. Tullos, S. Panozzo, M. Bhutani, F. Rhee, B. Barlogie, S. Usmani (2015)
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomibBlood Cancer Journal, 5
G. Srkalović, M. Cameron, L. Rybicki, S. Deitcher, Kandice Kattke-Marchant, M. Hussein (2004)
Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic diseaseCancer, 101
Michael Wang, D. Weber, K. Delasalle, R. Alexanian (2005)
Thalidomide–dexamethasone as primary therapy for advanced multiple myelomaAmerican Journal of Hematology, 79
K. Zervas, D. Mihou, E. Katodritou, A. Pouli, C. Mitsouli, A. Anagnostopoulos, Souzana Delibasi, M. Kyrtsonis, N. Anagnostopoulos, E. Terpos, P. Zikos, A. Maniatis, M. Dimopoulos (2007)
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.Annals of oncology : official journal of the European Society for Medical Oncology, 18 8
S. Kristinsson, T. Fears, G. Gridley, I. Turesson, U. Mellqvist, M. Björkholm, O. Landgren (2008)
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.Blood, 112 9
L. Nayak, Hong Shi, G. Atkins, Zhiyong Lin, A. Schmaier, M. Jain (2014)
The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2).Blood, 123 24
K. Miller, S. Padmanabhan, Laurie Dimicelli, D. Depaolo, B. Landrigan, Jihnhee Yu, Virginia Doran, Pat Marshal, A. Chanan-Khan (2006)
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolismLeukemia & Lymphoma, 47
R. Baz, Liang Li, K. Kottke-Marchant, G. Srkalović, B. McGowan, E. Yiannaki, M. Karam, B. Faiman, R. Jawde, S. Andresen, J. Zeldis, M. Hussein (2005)
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.Mayo Clinic proceedings, 80 12
J. San-Miguel, V. Hungria, Sung-Soo Yoon, M. Beksaç, M. Dimopoulos, A. Elghandour, W. Jędrzejczak, A. Günther, T. Nakorn, N. Siritanaratkul, P. Corradini, S. Chuncharunee, Je-Jung Lee, R. Schlossman, T. Shelekhova, K. Yong, D. Tan, T. Numbenjapon, J. Cavenagh, J. Hou, R. LeBlanc, H. Nahi, L. Qiu, H. Salwender, S. Pulini, P. Moreau, K. Warzocha, D. White, J. Bladé, Wenming Chen, J. Rubia, P. Gimsing, S. Lonial, J. Kaufman, E. Ocio, Ljupco Veskovski, S. Sohn, Ming-Chung Wang, Jae Lee, H. Einsele, M. Sopala, C. Corrado, B. Bengoudifa, F. Binlich, P. Richardson (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.The Lancet. Oncology, 15 11
E. Kastritis, M. Dimopoulos (2012)
When a little aspirin may be enough.Blood, 119 4
M. Lacy, S. Hayman, M. Gertz, K. Short, A. Dispenzieri, Shaji Kumar, P. Greipp, J. Lust, S. Russell, D. Dingli, S. Zeldenrust, R. Fonseca, P. Bergsagel, V. Roy, J. Mikhael, A. Stewart, K. Laumann, J. Allred, S. Mandrekar, S. Rajkumar, F. Buadi (2010)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)Leukemia, 24
S. Lonial, P. Richardson, J. Miguel, P. Sonneveld, M. Schuster, J. Bladé, J. Cavenagh, S. Rajkumar, A. Jakubowiak, D. Esseltine, K. Anderson, J. Harousseau (2008)
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaBritish Journal of Haematology, 143
H. Hassoun, L. Reich, V. Klimek, M. Dhodapkar, A. Cohen, T. Kewalramani, Rachel Zimman, L. Drake, E. Riedel, C. Hedvat, J. Teruya-Feldstein, D. Filippa, M. Fleisher, S. Nimer, R. Comenzo (2006)
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaBritish Journal of Haematology, 132
B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, F. Rhee, A. Fassas, M. Zangari, K. Hollmig, M. Pineda‐Roman, Choon-kee Lee, G. Talamo, R. Thertulien, E. Kiwan, S. Krishna, M. Fox, J. Crowley (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.The New England journal of medicine, 354 10
W. Stansfield, Ruhang Tang, N. Moss, A. Baldwin, M. Willis, C. Selzman (2008)
Proteasome inhibition promotes regression of left ventricular hypertrophy.American journal of physiology. Heart and circulatory physiology, 294 2
A. Chari, Daher Hajje (2014)
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoringBMC Cancer, 14
A. Larocca, F. Cavallo, S. Bringhen, F. Raimondo, A. Falanga, A. Evangelista, M. Cavalli, A. Stanevsky, P. Corradini, S. Pezzatti, F. Patriarca, M. Cavo, J. Peccatori, L. Catalano, A. Carella, A. Cafro, A. Siniscalchi, C. Crippa, M. Petrucci, D. Yehuda, E. Beggiato, T. Toritto, M. Boccadoro, A. Nagler, A. Palumbo (2012)
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.Blood, 119 4
J. Zonder, B. Barlogie, B. Durie, J. Mccoy, J. Crowley, M. Hussein (2006)
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.Blood, 108 1
J. Pye, Farhad Ardeshirpour, Arlene McCain, D. Bellinger, E. Merricks, J. Adams, P. Elliott, C. Pien, T. Fischer, A. Baldwin, T. Nichols (2003)
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.American journal of physiology. Heart and circulatory physiology, 284 3
A Palumbo, K Anderson (2011)
Multiple myeloma, 364
S. Arastu‐Kapur, J. Anderl, M. Kraus, F. Parlati, K. Shenk, Susan Lee, T. Muchamuel, M. Bennett, C. Driessen, A. Ball, C. Kirk (2011)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse EventsClinical Cancer Research, 17
KM Kortuem, AK Stewart (2013)
Carfilzomib, 121
S. Rajkumar, S. Hayman, M. Gertz, A. Dispenzieri, M. Lacy, P. Greipp, S. Geyer, N. Iturria, R. Fonseca, J. Lust, R. Kyle, T. Witzig (2002)
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 21
A. Gandhi, Jian Kang, C. Havens, Thomas Conklin, Y. Ning, Lei Wu, Takumi Ito, H. Ando, M. Waldman, A. Thakurta, A. Klippel, H. Handa, T. Daniel, P. Schafer, R. Chopra (2013)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBNBritish Journal of Haematology, 164
T. Hiroi, Clayton Deming, Haige Zhao, B. Hansen, E. Arkenbout, T. Myers, M. McDevitt, J. Rade (2009)
Proteasome Inhibitors Enhance Endothelial Thrombomodulin Expression via Induction of Krüppel-Like Transcription FactorsArteriosclerosis, Thrombosis, and Vascular Biology, 29
Ramzi Accaoui, W. Shamseddeen, A. Taher (2007)
Thalidomide and thrombosisThrombosis and Haemostasis, 97
M. Minnema, M. Veer, T. Aarts, M. Emmelot, T. Mutis, H. Lokhorst (2009)
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cellsLeukemia, 23
M. Lacy, M. Gertz, A. Dispenzieri, S. Hayman, S. Geyer, B. Kabat, S. Zeldenrust, Shaji Kumar, P. Greipp, R. Fonseca, J. Lust, S. Russell, R. Kyle, T. Witzig, P. Bergsagel, A. Stewart, S. Rajkumar, Hematology Oncol-Ogy, Mayo Clinic, Az Scottsdale (2007)
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.Mayo Clinic proceedings, 82 10
Aspire Investigators (2015)
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.The New England journal of medicine, 372 2
J. Mikhael, V. Rajkumar, V. Roy, S. Hayman, R. Fonseca, K. Short, B. Laplant, K. Laumann, A. Dispenzieri, M. Lacy (2011)
Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
R. Raddino, M. Gavazzoni, F. Pasini, E. Gorga, E. Vizzardi, I. Bonadei, T. Scarabelli (2015)
Cardiovascular toxicity of carfilzomib on vascular tone, vascular reactivity and endothelial functionVascular Pharmacology, 75
M. Zangari, L. Fink, F. Zhan, G. Tricot (2011)
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.Clinical lymphoma, myeloma & leukemia, 11 2
H. Chang, Jae Lee, Y. Do, S. Bae, Junglim Lee, S. Nam, Sung-Soo Yoon, S. Bang (2011)
A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple MyelomaThe Korean Journal of Internal Medicine, 26
B. Augustson, G. Begum, J. Dunn, Nicola Barth, F. Davies, G. Morgan, J. Behrens, Alastair Smith, J. Child, M. Drayson (2005)
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 36
RN El Accaoui, WA Shamseddeen, AT Taher (2007)
Thalidomide and thrombosis. A meta-analysis, 97
X. Chang, Y. Zhu, C. Shi, A. Stewart (2014)
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Acta biochimica et biophysica Sinica, 46 3
M. Offidani, L. Corvatta, M. Marconi, A. Olivieri, M. Catarini, A. Mele, M. Brunori, M. Candela, L. Malerba, D. Capelli, M. Montanari, P. Leoni (2004)
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma.The hematology journal : the official journal of the European Haematology Association, 5 4
Margarita Bockorny, Saneka Chakravarty, P. Schulman, B. Bockorny, R. Bona (2012)
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the LiteratureActa Haematologica, 128
M. Offidani, L. Corvatta, Maria‐Novella Piersantelli, G. Visani, F. Alesiani, M. Brunori, P. Galieni, M. Catarini, M. Burattini, R. Centurioni, M. Ferranti, S. Rupoli, A. Scortechini, L. Giuliodori, M. Candela, D. Capelli, M. Montanari, A. Olivieri, A. Poloni, C. Polloni, M. Marconi, P. Leoni (2006)
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.Blood, 108 7
T. Scarabelli, C. Chen-Scarabelli, M. Gavazzoni, G. Sahni, L. Saravolatz, R. Raddino, J. Narula (2015)
CARDIOVASCULAR EFFECTS OF CARFILZOMIB, A NEW PROTEASOME INHIBITOR, ON CORONARY RESISTENCIES, VASCULAR TONE AND VASCULAR REACTIVITYJournal of the American College of Cardiology, 65
J. Krönke, N. Udeshi, A. Narla, Peter Grauman, Slater Hurst, M. McConkey, Tanya Svinkina, D. Heckl, Eamon Comer, Xiaoyu Li, Christie Ciarlo, Emily Hartman, N. Munshi, M. Schenone, S. Schreiber, S. Carr, B. Ebert (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma CellsScience, 343
K. Stangl, V. Stangl (2010)
The ubiquitin-proteasome pathway and endothelial (dys)function.Cardiovascular research, 85 2
ImportanceMultiple myeloma (MM) is the second most common hematological malignant abnormality. The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has greatly improved the overall survival of patients with MM. Prevention and treatment of cardiovascular and thrombotic issues associated with novel MM therapies have emerged as important aspects of supportive care in patients with MM. ObservationsWe searched PubMed and the Cochrance database for studies published from March 2001 to January 2016. Emerging evidence suggests that both IMiDs and PIs can have cardiovascular (CV) sequelae, which include thromboembolic complications, cardiac, and vascular toxic effects. These complications occur against the backdrop of a high prevalence of CV disease in the MM population as well as the adverse cardiac and vascular effects of MM itself. Conclusions and RelevanceThis review provides an overview of the incidences, clinical presentations, and mechanisms of CV complications in the MM population. We conclude that more research is needed for better screening and preventive strategies to abrogate these toxic effects and improve patient care.
JAMA Oncology – American Medical Association
Published: Jul 15, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.